SCHEMBL2608540

SCHEMBL2608540

CSc1ccccc1-c1nc2cccc(F)c2c(Cl)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBNL1 Q9NR56 1/20 0.39
KCNN4 O15554 1/20 0.38
PIK3CA P42336 2/20 0.36
ELANE P08246 1/20 0.36
PARP1 P09874 1/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
NISCH Q9Y2I1 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
P2RX7 Q99572 2/20 0.33
DHODH Q02127 2/20 0.33
ALOX5 P09917 1/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124507 0.86 MBNL1 (0.51) MBNL1PIK3CAELANEPARP1KMT2A
SCHEMBL2123958 0.85 PIK3CA (0.35) MBNL1KCNN4PIK3CAKMT2AKDM4E
SCHEMBL2123216 0.79 ELANE (0.51) MBNL1PIK3CAELANEPARP1KMT2A
SCHEMBL2125770 0.76 DHODH (0.38) MBNL1PARP1DHODHALOX5
SCHEMBL2124157 0.76 ACHE (0.43) PIK3CAKMT2AKDM4ENPC1ALDH1A1
SCHEMBL244335 0.74 NPC1 (0.48) PIK3CAPARP1KMT2AKDM4ENPC1
SCHEMBL13063627 0.73 MBNL1 (0.55) MBNL1PIK3CAELANEPARP1NPC1
SCHEMBL2126781 0.73 PARP1 (0.46) ELANEPARP1
SCHEMBL2711237 0.72 ALOX5AP (0.35) KDM4EDHODHALOX5APFEN1
SCHEMBL2710938 0.72 MBNL1 (0.48) MBNL1PIK3CADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 MBNL1 1806/4885KCNN4 4045/4885PIK3CA 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.